Evotec AG Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (34)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Evotec AG - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Evotec AG. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in research phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Evotec AG - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Evotec AG - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Evotec AG. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in research phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Evotec AG - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Evotec AG

  1.1 Business Overview

  1.2 Evotec AG Cancer Pipeline Overview

 

2. Evotec Cancer Drugs in Research Phase

  2.1 RhoB Modulators - Evotec/Inserm Transfert

  2.2 Immuno-Oncology Therapies - Evotec/Ex Scientia

  2.3 Small Molecule-Based Cancer Immunotherapeutics - Apeiron Biologics/Evotec/Sanofi

  2.4 Cancer Therapeutics - Evotec AG/The Ohio State University Comprehensive Cancer Center

  2.5 Cancer Therapeutics - Evotec/Debiopharm

  2.6 Haematological Malignancy Therapeutics - Evotec / Leukemia & Lymphoma Society

 

3. Evotec Cancer Drugs in Preclinical Phase

  3.1 E3 Ubiquitin Ligase Inhibitors - Apeiron Biologics1

  3.2 Cancer And Diabetes Therapeutics - Evotec/Sanofi

  3.3 Drug Discovery - Evotec/Genentech

  3.4 Small Molecule Therapeutics - Boehringer Ingelheim/Evotec AG

 

4. Evotec Cancer Drugs in Phase-I

  4.1 BI 860585

 

5. No Development Reperted in Cancer Drugs in Clinical Pipeline

  5.1 Cancer Drug Discovery - Dana-Farber Cancer Institute / Evotec

  5.2 Small Molecule Immunotherapy Therapeutics - Active Biotech/Evotec

  5.3 Drug Discovery - Evotec/Yale University

 

6. Discontinued in Cancer Drugs in Clinical Pipeline

  6.1 Proto Oncogene Proteins C-Akt Inhibitors - DeveloGen

  6.2 Hsp60 Cancer Vaccine - DeveloGen

  6.3 Bcl-2/Bcl-xl/Mcl-1 Inhibitors - Evotec

  6.4 Heat Shock Protein 90 Modulators - Evotec AG/Genextra

  6.5 Pinal Cord Injury And Cancer Therapies - Renovis/Genentech

  6.6 p16/p53 Gene Therapy - DeveloGen


Figure 1-1: Evotec AG Cancer Pipelinie by Phase (%)

Figure 1-2: Evotec AG Cancer Pipelinie by Phase (Number)

Figure 1-3: Evotec AG Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Evotec AG Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)